Thyroid function in multidrug-resistant tuberculosis patients with or without human immunodeficiency virus (HIV) infection before commencement of MDR-TB drug regimen by Ige, Olusoji Mayowa et al.
Thyroid function in multidrug-resistant tuberculosis patients with or without human 
immunodeficiency virus (HIV) infection before commencement of  MDR-TB drug regimen.
Olusoji Mayowa Ige1, Kehinde Sola Akinlade2, Sheu Kadiri Rahamon2, Victory Fabian Edem2, 
Olatunbosun Ganiyu Arinola2
1. Department of  Medicine, University of  Ibadan/University College Hospital, Ibadan, Nigeria.
2. Deaprtment of  Chemical Pathology, University of  Ibadan/University College Hospital, Ibadan, Nigeria.
Abstract
Background: Mycobacterium tuberculosis and human immunodeficiency virus (HIV) are known to cause abnormal thyroid 
function. There is little information on whether HIV infection aggravates alteration of  thyroid function in patients with MDR-
TB.
Objectives: This study was carried out to determine if  HIV co-infection alters serum levels of  thyroid hormones (T3, T4) and 
thyroid stimulating hormone (TSH) in patients with MDR-TB patients and to find out the frequency of  subclinical thyroid dys-
function before the commencement of  MDR-TB therapy.
Methods: This observational and cross-sectional study involved all the newly admitted patients in MDR-TB Referral Centre, 
University College Hospital, Ibadan, Nigeria between July 2010 and December 2014. Serum levels of  thyroid stimulating hor-
mone (TSH), free thyroxine (fT4) and free triiodothyronine (fT3) were determined using ELISA.
Results: Enrolled were 115 patients with MDR-TB, out of  which 22 (19.13%) had MDR-TB/HIV co-infection. Sick euthy-
roid syndrome (SES), subclinical hypothyroidism and subclinical hyperthyroidism were observed in 5 (4.35%), 9 (7.83%) and 
2 (1.74%) patients respectively. The median level of  TSH was insignificantly higher while the median levels of  T3 and T4 were 
insignificantly lower in patients with MDR-TB/HIV co-infection compared with patients with MDRT-TB only.
Conclusion: It could be concluded from this study that patients with MDR-TB/HIV co-infection have a similar thyroid func-
tion as patients having MDR-TB without HIV infection before commencement of  MDR-TB drug regimen. Also, there is a 
possibility of  subclinical thyroid dysfunction in patients with MDR-TB/HIV co-infection even, before the commencement of  
MDR-TB therapy.
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Introduction
Multidrug-resistant tuberculosis (MDR-TB) continues 
to be a public health problem because of  its increasing 
trend1,2. Due to the ineffectiveness of  two most effec-
tive anti-TB drugs (isoniazid and rifampicin), treatment 
of  MDR-TB becomes challenging as it involves combina-
tion of  a minimum of  5 drugs for at least 20 months3,4.
Management of  MDR-TB is daunting especially, when 
it co-exists with HIV infection. It has been shown that 
management of  MDR-TB or MDR-TB with HIV co-
infection is associated with some adverse events such as 
alteration in thyroid hormone levels4,5,6. Thus, the need 
to determine the status of  thyroid hormones before the 
commencement of  therapy cannot be over emphasized.
The thyroid gland plays an important role in the mainte-
nance of  body metabolism. Principally, it secretes thyrox-
ine (T4) and triiodothyronine (T3)under the influence of  
thyroid stimulating hormones7,8. Reports have shown that 
there is alteration in thyroid hormone levels in patients 
with non-thyroid illnesses such as TB. This alteration has 
been attributed to anti-TB drugs especially, the second-
line anti-TB drugs which cause more adverse effects 
than the first-line anti-TB drugs used for the treatment 
of  drug-sensitive TB9. The exact mechanism responsible 
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for the alteration is still unknown8,10, though the follow-
ing mechanisms were suggested; viz: decreased T4 to T3 
conversion, decreased TSH production and action of  
drugs such as ethionamide and prothionamide used for 
the treatment of  MDR-TB on the thyroid causing hy-
pothyroidism by inhibiting thyroid hormone synthesis 
through inhibition of  iodine organification11-13. Similarly, 
antiretroviral therapies such as stavudine, amprenavir and 
lopinavir have been associated with hypothyroidism14,15. 
It is therefore important to assess thyroid function test 
before commencement of  MDR drug regimen.
Although WHO guidelines recommended that TSH level 
should be monitored in patients with MDR-TB at least 
every 6 months12, there is lack of  information on whether 
HIV infection has an additional effect on the alteration 
of  thyroid hormones in patients with MDR-TB.  Infor-
mation on thyroid hormone status of  MDR-TB patients 
will identify MDR-TB patients with subclinical thyroid 
dysfunction who might benefit from appropriate clini-
cal intervention before the commencement of  MDR-
TB drug regimen which could get worse with the com-
mencement of  the therapy. To provide information on 
thyroid function in Nigerian MDR-TB patients with HIV 
co-infection, we determined the serum levels of  thyroid 




This observational and cross-sectional study involved all 
the MDR-TB patients admitted at the MDR-TB Referral 
Centre, University College Hospital, Ibadan, Nigeria be-
tween July 2010 and December 2014. Enrolled were 115 
patients with MDR-TB, out of  which 22 (19.13%) had 
MDR-TB/HIV co-infection.
Data collection
Height (m), body weight (kg) and body mass index (kg/
m2) were taken using standard methods. Serum levels of  
TSH, free T4 (fT4) and free T3 (fT3) were determined 
using ELISA (Biotek, USA). Assessment of  thyroid func-
tion is part of  the pre-treatment medical assessment usu-
ally carried out on patients referred to the MDR-TB Unit 
of  the hospital and 0.4 – 4.0 IU/ml, 59 – 153 nmol/L 
and 0.56 – 1.88 ng/ml were considered as the reference 
ranges for TSH, T4 and T3 respectively.
Statistical analysis
The distribution of  all the variables was assessed using 
histogram with normal curve. All the variables except 
TSH, fT4 and fT3 had Gaussian distribution. Depending 
on the Gaussian distribution, differences of  variables be-
tween groups were assessed using the Student’s t, Mann 
Whitney U and Fisher’s exact test. Results are presented 
as mean ± standard deviation or median (interquartile 
range). P values less than 0.05 were considered as statisti-
cally significant. 
Results
Majority of  the patients had normal thyroid profile. Five 
(4.35%), 9 (7.83%) and 2 (1.74%) patients had sick eu-
thyroid syndrome (normal TSH level with low T3 and/
or T4 level), subclinical hypothyroidism (high TSH with 
normal T3 and T4) and subclinical hyperthyroidism (low 
TSH with normal T3 and T4) respectively.
As shown in Table 1, the median level of  TSH was slightly 
higher while the median levels of  T3 and T4 were slightly 
lower in patients with MDR-TB/HIV co-infection com-
pared with MDR-TB patients only. However, the differ-
ences in the medians were not statistically significant. 
Similarly, the mean body weight and BMI were similar 
between the 2 groups.
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Table 1: Demographic characteristics, thyroid stimulating hormone and thyroid hormones 
levels in MDR-TB patients with or without HIV infection 
  MDR-TB 
 (n = 93) 
MDR-TB/HIV 
   (n = 22) 
P-values 
Age (years) 35.44 ± 11.07 33.18 ± 9.18 0.377 
Height (m) 1.63 ± 0.26 1.66 ± 0.11 0.617 
Body weight (kg) 48.40 ± 13.26 50.27 ± 8.75 0.530 
BMI (kg/m2) 16.95 ± 4.91 18.13 ± 2.58 0.276 
TSH (IU/ml) 1.85 (1.13 – 3.48) 1.90(1.38 – 2.48) 0.822 
fT4 (nmol/L) 91.00 (70.00 – 107.00) 88.00 (62.75 – 103.70) 0.516 
fT3 (ng/ml) 1.15 (0.75 – 1.60) 1.12 (0.69 – 1.65) 0.797 
BMI= body mass index, TSH=thyroid stimulating hormone, fT4 =free thyroxine, fT3 = 
free triiodothyronine, values are presented in mean ± standard deviation or median (interquartile range)  
When all the patients were pooled and compared based 
on gender (males and females), it was observed that the 
median levels of  TSH, T3 and T4 were similar between 
the 2 groups. However, male patients were found to be 
significantly older and had higher BMI than the female 
patients (Table 2).
There was no difference in the median levels of  TSH, 
T3 and T4 when male patients with MDR-TB/HIV co-
infection were compared with male patients with MDR-
TB only (Table 3). 
 Table 2: Demographic characteristics, thyroid stimulating hormone and thyroid hormones 
levels in male and female MDR-TB patients without HIV infection and MDR-TB patients 
with HIV infection 
  Male (n = 76) Female (n = 39) P-value 
Age (years) 37.30 ± 11.04 30.54 ± 8.64 0.001* 
Height (m) 1.65 ± 0.28  1.61 ± 0.10 0.395 
Body weight (kg) 51.62± 13.03 43.33 ± 9.37 0.001* 
BMI (kg/m2) 17.44 ± 5.12 16.65 ± 3.26 0.385 
TSH (IU/ml) 1.80 (1.20 – 3.40) 1.90 (1.20 – 3.50) 0.908 
fT4 (nmol/L) 87.00 (67.10 – 101.50) 93.00 (70.00 – 112.00)   0.116 
fT3 (ng/ml) 1.00 (0.75 – 1.75) 1.20 (0.73 – 1.50) 0.895 
*Significant at P<0.05, BMI= body mass index, TSH=thyroid stimulating 
hormone, fT4 =free thyroxine, fT3 = free triiodothyronine, values are presented in mean ± standard 
deviation or median (interquartile range)  
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Similarly, the median levels of  TSH, T3 and T4 were simi-
lar in female patients with MDR-TB/HIV co-infection 
and female patients with MDR-TB only (Table 4).
Table 3: Demographic characteristics, thyroid stimulating hormone and thyroid hormones 
levels in male MDR-TB patients without HIV infection and male  
MDR-TB patients with HIV infection 
 
  MDR-TB 
(n = 65) 
MDR-TB/HIV 
  (n = 11) 
P-value 
Age (years) 33.83 ± 8.44 40.64 ± 17.44 0.231 
Height (m) 1.64 ± 0.30 1.72 ± 0.04 0.397 
Body weight (kg) 51.22 ± 13.94 53.91 ± 5.28 0.532 
BMI (kg/m2) 17.30± 5.48 18.26 ± 1.78 0.570 
TSH (IU/ml) 1.80 (1.18 – 3.83) 2.10 (1.60 – 2.40) 0.823 
fT4 (nmol/L) 91.00 (67.80 – 104.00) 80.00 (62.00 – 92.00) 0.226 
fT3 (ng/ml) 1.00 (0.75 – 1.83) 1.14 (0.65 – 1.70) 0.688 
BMI= body mass index, TSH=thyroid stimulating hormone, fT4 =free thyroxine, fT3 = 
free triiodothyronine, values are presented in mean ± standard deviation or median (interquartile 
range)  
 
Table 4: Demographic characteristics, thyroid stimulating hormone and thyroid hormones  
levels in female MDR-TB patients without HIV infection and female 
 MDR-TB patients with HIV infection 
 
  MDR-TB 
(n = 28) 
MDR-TB/HIV 
  (n = 11) 
P-value 
Age (years) 35.04 ± 12.26 36.27 ± 10.17  0.769 
    Height(m)                                1.62 ± 0.09   1.60 ± 0.13                        0.737                  
Body weight (kg)    42.04 ± 8.88  46.64 ± 10.19                     0.171  
BMI (kg/m2) 16.12 ± 3.15 18.00 ± 3.28                   0.106  
TSH (IU/ml) 2.35 (1.10 – 3.53) 1.70 (1.25 – 3.75)               0.955  
fT4 (nmol/L) 92.00 (69.50 – 112.00) 101.00 (63.50 – 115.00)    0.985  
fT3 (ng/ml) 1.20 (0.71 – 1.50) 1.10 (0.79 – 1.45)               0.806  
BMI= body mass index, TSH=thyroid stimulating hormone, fT4 =free thyroxine, fT3 = 
free triiodothyronine, values are presented in mean ± standard deviation or median (interquartile 
range)  
Table 4: Demographic characteristics, thyroid stimulating hormone and thyroid hormones  
levels in fem le MDR-TB patients withou  HIV infection and female 
 MDR-TB patients with HIV infection 
 
  MDR-TB 
(n = 28) 
MDR-TB/HIV 
  (n = 11) 
P-value 
Age (years) 35.04 ± 12.26 36.27 ± 10.17  0.769 
    Height(m)                                1.62 ± 0.09   1.60 ± 0.13                        0.737                  
Body weight (kg)    42.04 ± 8.88  46.64 ± 10.19                     0.171  
BMI (kg/m2) 16.12 ± 3.15 18.00 ± 3.28                   0.106  
TSH (IU/ml) 2.35 (1.10 – 3.53) 1.70 (1.25 – 3.75)               0.955  
fT4 (nmol/L) 92.00 (69.50 – 112.00) 101.00 (63.50 – 115.00)    0.985  
fT3 (ng/ml) 1.20 (0.71 – 1.50) 1.10 (0.79 – 1.45)               0.806  
BMI= body mass index, TSH=thyroid stimulating hormone, fT4 =free thyroxine, fT3 = 
free triiodothyronine, values are presented in mean ± standard deviation or m dian (interquartile 
range)  
Table 4: Demographic characteristics, thyroid stimulating hormone and thyroid hormones  
levels in female MDR-TB patients wi ho t HIV infection  female 
 -  patients ith HIV infection 
 
  MDR-TB 
(n = 28) 
MDR-TB/HIV 
  (n = 11) 
P-value 
Age (years) 35.04 ± 12.26 36.27 ± 10.17  0.769 
    Height(m)                                1.62 ± 0.09   1.60 ± 0.13                        0.737                  
Body weight (kg)    42.04 ± 8.88  46.64 ± 10.19                     0.171  
BMI (kg/m2) 16.12 ± 3.15 18.00 ± 3.28                   0.106  
TSH (IU/ml) 2.35 (1.10 – 3.53) 1.70 (1.25 – 3.75)               0.955  
fT4 (nmol/L) 92.00 (69.50 – 112.00) 101.00 (63.50 – 115.00)    0.985  
fT3 (ng/ml) 1.20 (0.71 – 1.50) 1.10 (0.79 – 1.45)               0.806  
BMI= body mass index, TSH=thyroid stimulating hormone, fT4 =free thyroxine, fT3 = 
free triiod th ronine, values are presented in mean ± sta dard deviation or median (interquartile 
range)  
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In Table 5, there was no significant association between HIV status and levels of  TSH, T3 and T4.     
Table 5: Association between MDR-TB/HIV co-infection, thyroid stimulating hormone and 
thyroid hormones in MDR-TB patients without HIV infection and MDR-TB patients with HIV 
infection 
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Discussion
The need for detection of  thyroid disease in patients with 
MDR-TB cannot be under-estimated since reports have 
shown that subclinical hypothyroidism increases the risk 
of  depression and reduces adherence to MDR-TB and 
HIV treatment16,17.
An independent association between chronic illnesses 
such as tuberculosis and thyroid disease has been report-
ed18,19. This might explain the observed SES, subclinical 
hypothyroidism and subclinical hyperthyroidism in our 
patients.
Reports have shown that HIV and TB infections cause 
alteration in thyroid function5,6. In this study, there was 
no significant difference in the median levels of  thyroid 
stimulating hormone and thyroid hormones in patients 
with MDR-TB only and those with MDR-TB/HIV co-
infection. This observation suggests that MDR-TB/HIV 
co-infection and MDR-TB infection have similar effects 
son thyroid function.
Modongo and Zetola20 reported that there is an associa-
tion between male gender and the development of  hy-
pothyroidism in patients with MDR-TB on treatment. 
The median levels of  thyroid stimulating hormone and 
thyroid hormones were similar between the male and fe-
male patients. Our observation shows that the effect of  
the illness on thyroid stimulating hormone and thyroid 
hormones levels might not be gender specific.  However, 
male MDR-TB patients were observed to be older and 
with higher body weight than female patients. Comparing 
the male patients with MDR-TB only with male patients 
with MDR-TB/HIV co-infection, there was no signifi-
cant difference in the median levels of  thyroid stimulating 
hormone and thyroid hormones. A similar pattern was 
also observed when female patients with MDR-TB only 
were compared with female patients with MDR-TB/HIV 
co-infection. These observations further support our ear-
lier observation that the effect of  the illnesses on the thy-
roid function might not be gender specific.
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The observed lack of  association between HIV status 
and thyroid stimulating hormone/thyroid hormones lev-
els is in line with our observed non-significant difference 
in the median levels of  thyroid stimulating hormone and 
thyroid hormones in patients with MDR-TB only and 
patients with MDR-TB/HIV co-infection. This observa-
tion shows that the presence of  HIV infection does not 
seem to alter the thyroid function in MDR-TB patients 
before the commencement of  MDR-TB drugs.
It could be concluded from this study that patients with 
MDR-TB/HIV co-infection have similar thyroid func-
tion compared with patients having MDR-TB without 
HIV infection before the commencement of  MDR-TB 
drugs. However, the presence of  SES and subclinical 
thyroid dysfunction in some of  the patients indicates the 
need to assess thyroid function in MDR-TB patients with 
or without HIV infection before commencing MDR-
TB therapy as it could identify patients that might ben-
efit from appropriate clinical intervention with a view to 
preventing aggravation of  the thyroid disease during the 
course of  the MDR-TB therapy.
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